Mirabella Financial Services LLP Purchases Shares of 4,131 argenx SE (NASDAQ:ARGX)

Mirabella Financial Services LLP acquired a new stake in argenx SE (NASDAQ:ARGX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 4,131 shares of the company's stock, valued at approximately $2,539,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. GeoWealth Management LLC boosted its position in argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after buying an additional 18 shares during the period. Steward Partners Investment Advisory LLC boosted its holdings in argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock valued at $234,000 after acquiring an additional 20 shares during the period. SG Americas Securities LLC grew its position in argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company's stock worth $220,000 after acquiring an additional 21 shares during the last quarter. Farther Finance Advisors LLC increased its stake in argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock worth $47,000 after purchasing an additional 21 shares during the period. Finally, Dynasty Wealth Management LLC increased its stake in argenx by 3.4% in the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company's stock worth $416,000 after purchasing an additional 22 shares during the period. Institutional investors own 60.32% of the company's stock.

argenx Trading Down 0.9 %

ARGX stock traded down $5.22 during midday trading on Wednesday, reaching $594.65. 244,073 shares of the company's stock traded hands, compared to its average volume of 308,372. The stock's 50-day moving average is $599.54 and its 200 day moving average is $606.69. The stock has a market cap of $36.31 billion, a P/E ratio of -675.74 and a beta of 0.60. argenx SE has a 52-week low of $352.77 and a 52-week high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. As a group, research analysts expect that argenx SE will post 3.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ARGX. Wedbush reiterated an "outperform" rating and set a $715.00 target price on shares of argenx in a report on Friday, April 11th. Guggenheim increased their price objective on argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Robert W. Baird boosted their target price on argenx from $650.00 to $680.00 and gave the company a "neutral" rating in a research note on Tuesday, March 4th. Piper Sandler upped their target price on argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a report on Tuesday, January 7th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. Three research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $699.28.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.